While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors rely on traditional forms of analysis on key valuation metrics to fi ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sarepta Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the safety of its drug ELEVIDYS [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Sarepta between June 22, 2023, and June 24, 2025, to discuss their legal rights [1]. - There is an August 25, 2025, deadline for investors to seek the role of lead plaintiff in a federal securities class action against Sarepta [2]. - The complaint alleges that Sarepta and its executives made false statements regarding the safety of ELEVIDYS, which posed significant risks to patients [4]. Group 2: Stock Price Impact - Following a safety update on March 18, 2025, Sarepta's stock price fell by $27.81 per share, or 27.44%, closing at $73.54 [5]. - On April 4, 2025, after disclosing regulatory scrutiny, the stock price dropped by $4.18 per share, or 7.13%, closing at $54.43 [6]. - A second patient death reported on June 15, 2025, led to a significant stock price decline of $15.24 per share, or 42.12%, closing at $20.91 [8]. - Following an FDA Safety Communication on June 24, 2025, the stock price fell by $1.52 per share, or 8.01%, closing at $17.46 [9]. Group 3: Company Background - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in multiple states [3].

Key Takeaways Tempus AI now expects 2025 revenues of $1.25B and adjusted EBITDA of $5M, both raised from prior guidance. TEM's Q1 sales surged 75.4% and gross profit nearly doubled on lab gains and a higher data services mix. TEM's deals with AstraZeneca and Pathos and hereditary testing growth from Ambry Genetics drove guidance hike.Tempus AI (TEM) expects full-year 2025 revenues of $1.25 billion (up from the previous $1.24 billion guidance), which represents approximately 80% annual growth. The company ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Sino Biopharmaceutical says it will take over the privately held Chinese biotech company LaNova Medicines https://t.co/2cfh2Kwp0r ...

Core Points - IMUNON, Inc. has received approval from the Nasdaq Hearing Panel for an exception to complete its compliance plan, allowing the company to maintain its Nasdaq listing [1][2] - The Nasdaq Hearing Panel noted that IMUNON has achieved compliance with the Equity Rule through recent fundraising activities and will implement a compliance plan to meet minimum shareholder equity and bid price requirements [2][3] - The Panel approved a tailored exception for IMUNON to regain compliance within a designated timeframe, rather than the full 180 days initially requested [3] Company Overview - IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments that utilize the body's natural mechanisms to generate effective responses against various diseases [5] - The company is advancing its non-viral DNA technology, with its lead clinical program, IMNN-001, being a DNA-based immunotherapy for advanced ovarian cancer [6] - IMNN-001 has completed multiple clinical trials, including a Phase 2 trial, and the company has also conducted a first-in-human study for its COVID-19 booster vaccine, IMNN-101 [6]

Core Viewpoint - Clearmind Medicine Inc. is expanding its Phase I/IIa clinical trial for CMND-100, a treatment for Alcohol Use Disorder (AUD), by activating a new site at Johns Hopkins University and enrolling its first participant there, indicating positive momentum in its clinical development program [1][2][3]. Group 1: Clinical Trial Details - The Phase I/IIa clinical trial aims to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, with preliminary efficacy indicators focusing on reducing alcohol cravings and consumption [2][4]. - The trial is a multinational, multicenter study that will explore early signals of efficacy, including reductions in alcohol consumption and cravings, which could facilitate further development of this therapy [4]. Group 2: Company Strategy and Goals - The activation of new clinical sites and participant enrollment is seen as a step closer to validating CMND-100's potential to transform the treatment landscape for AUD, reflecting the scientific community's interest in the company's approach [3][5]. - Clearmind's primary objective is to research and develop psychedelic-based compounds and commercialize them as regulated medicines, foods, or supplements, addressing widespread and underserved health problems [5]. Group 3: Intellectual Property - The company currently holds an intellectual portfolio consisting of nineteen patent families, including 31 granted patents, and plans to seek additional patents for its compounds as warranted [6].

SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter 2025 before market open on Thursday, July 31, 2025. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. ...

Dr. Lotan's distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada's NDV-01 program Yair Lotan, MD, is a urologic oncologist with over 20 years of experience caring for bladder cancer patients. Dr. Lotan graduated with high honors from the University of Texas at Austin and with honors from Baylor College of Medicine in Houston. He trained in general surgery and urology at UT Southwestern Medical Center in Dallas. Dr. Lotan heads a clinical researc ...

Core Viewpoint - Polyrizon Ltd. has received approval from the Nasdaq Hearings Panel to continue its listing on the Nasdaq Capital Market, following a plan to address concerns regarding its capital structure and compliance with listing standards [1][3]. Group 1: Nasdaq Listing and Compliance - The Nasdaq Listing Qualifications Department previously issued a public interest determination under Listing Rule 5101 due to the company's issuance of securities in a private placement, particularly concerning Series A warrants [2]. - A hearing was held on June 26, 2025, where Polyrizon presented its plan to avoid complex financing instruments in future capital-raising activities [3]. - The Panel's determination on July 9, 2025, allows the company to maintain its listing, contingent upon regaining compliance with the Minimum Bid Price Rule by October 17, 2025 [3]. Group 2: Financial Position and Capital Structure - Following the private placement, the company reported a cash balance of approximately $15.68 million, and all warrants issued in the transaction have been exercised, simplifying its capital structure [4]. - The elimination of a significant source of potential dilution is expected to enhance long-term shareholder value [4]. Group 3: Internal Controls and Future Plans - The company is implementing a formal internal control framework to govern future securities issuances and ensure compliance with Nasdaq standards, including enhanced oversight and quarterly internal compliance reviews [5]. Group 4: Company Overview - Polyrizon is a development stage biotech company focused on innovative intranasal hydrogels that create a barrier against viruses and allergens in the nasal cavity [5]. - The proprietary Capture and Contain hydrogel technology is designed to function as a "biological mask," and the company is also developing the Trap and Target technology for nasal delivery of active pharmaceutical ingredients [5].